23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › AMPHASTAR PHARMACEUTICALS INC. › 2023-2024

AMPHASTAR PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 299Asset managers, any item
  • 2,413Fund votes
  • June 3, 2024Meeting date

Results at a glance

Meeting of June 3, 2024: 7 items on AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2024: 4 elected · 3 approved.

Dissent

Significant dissent: 2 directors (27.2%, 22.7% against); 1 equity or compensation plan (29.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AMPHASTAR PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AMPHASTAR PHARMACEUTICALS INC.

These tallies are AMPHASTAR PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AMPHASTAR PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 3, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mary Ziping Luo 36,539,3613,238,76216,103 --4,897,137 92%Elected—
Elect Director: Howard Lee 30,735,0849,041,57317,569 --4,897,137 77%Elected—
Elect Director: Michael A. Zasloff 28,934,72110,836,43123,074 --4,897,137 73%Elected—
Elect Director: Gayle Deflin 37,568,6362,204,67920,911 --4,897,137 94%Elected—
2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 44,072,994586,01732,352 ---- 99%Approved—
3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and 37,859,7451,833,819100,662 --4,897,137 95%Approved—
4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan") 28,069,40111,693,21331,612 --4,897,137 71%Approved—

Source: AMPHASTAR PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 4, 2024 — read the filing on EDGAR.

How asset managers voted at the AMPHASTAR PHARMACEUTICALS INC. 2023-2024 meeting

299 asset managers disclosed a vote on at least one AMPHASTAR PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Gayle Deflin

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 37,568,636AGAINST: 2,204,679
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Gayle Deflin

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gayle Deflin”): 37,568,636 for, 2,204,679 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 16,015,958 for, 1,348,166 against, 4,323 abstained.

FOR
FOR: 16,015,958AGAINST: 1,348,166ABSTAIN: 4,323
Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust1,200,1920 00For
Neuberger Berman1,108,3100 00For
Dimensional0830,819 00Against
Fidelity794,1050 00For
State Street634,4301,578 00For
American Century634,4190 00For
T. Rowe Price0439,674 00Against
OBERWEIS FUNDS394,6000 00For
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC283,1350 00For
Invesco268,0410 00For
Victory Capital190,6150 00For
TIAA187,1110 00For
Janus Detroit Street Trust134,1390 00For
Brighthouse113,1122,376 00For
Equitable104,0010 00For
Columbia Threadneedle101,3390 00For
MoA Funds Corp96,3320 00For
Jackson National80,61413,624 00Mixed
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon71,1290 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Elect Director: Howard Lee

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST
FOR: 30,735,084AGAINST: 9,041,573
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Howard Lee

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Howard Lee”): 30,735,084 for, 9,041,573 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 12,077,606 for, 5,286,518 against, 4,323 abstained.

FORAGAINST
FOR: 12,077,606AGAINST: 5,286,518ABSTAIN: 4,323
Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust01,200,192 00Against
Neuberger Berman1,108,3100 00For
Dimensional0830,819 00Against
Fidelity752,00342,102 00Mixed
State Street628,6257,383 00For
American Century0634,419 00Against
T. Rowe Price0439,674 00Against
OBERWEIS FUNDS0394,600 00Against
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC0283,135 00Against
Invesco268,0410 00For
Victory Capital0190,615 00Against
TIAA0187,111 00Against
Janus Detroit Street Trust0134,139 00Against
Brighthouse101,04814,440 00Mixed
Equitable104,0010 00For
Columbia Threadneedle0101,339 00Against
MoA Funds Corp096,332 00Against
Jackson National094,238 00Against
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon071,129 00Against

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Elect Director: Mary Ziping Luo

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 36,539,361AGAINST: 3,238,762
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Mary Ziping Luo

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mary Ziping Luo”): 36,539,361 for, 3,238,762 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 15,779,001 for, 1,585,123 against, 4,323 abstained.

FOR
FOR: 15,779,001AGAINST: 1,585,123ABSTAIN: 4,323
Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust1,200,1920 00For
Neuberger Berman1,108,3100 00For
Dimensional0830,819 00Against
Fidelity794,1050 00For
State Street9,822626,186 00Against
American Century634,4190 00For
T. Rowe Price439,6740 00For
OBERWEIS FUNDS394,6000 00For
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC283,1350 00For
Invesco268,0410 00For
Victory Capital190,6150 00For
TIAA187,1110 00For
Janus Detroit Street Trust134,1390 00For
Brighthouse115,4880 00For
Equitable104,0010 00For
Columbia Threadneedle101,3390 00For
MoA Funds Corp96,3320 00For
Jackson National80,61413,624 00Mixed
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon71,1290 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Elect Director: Michael A. Zasloff

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST
FOR: 28,934,721AGAINST: 10,836,431
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Michael A. Zasloff

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael A. Zasloff”): 28,934,721 for, 10,836,431 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 11,105,723 for, 6,258,401 against, 4,323 abstained.

FORAGAINST
FOR: 11,105,723AGAINST: 6,258,401ABSTAIN: 4,323
Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust01,200,192 00Against
Neuberger Berman1,108,3100 00For
Dimensional0830,819 00Against
Fidelity752,00342,102 00Mixed
State Street4,017631,991 00Against
American Century0634,419 00Against
T. Rowe Price0439,674 00Against
OBERWEIS FUNDS0394,600 00Against
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC0283,135 00Against
Invesco0268,041 00Against
Victory Capital0190,615 00Against
TIAA0187,111 00Against
Janus Detroit Street Trust0134,139 00Against
Brighthouse101,04814,440 00Mixed
Equitable57,90146,100 00Mixed
Columbia Threadneedle0101,339 00Against
MoA Funds Corp096,332 00Against
Jackson National094,238 00Against
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon071,129 00Against

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the…

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

71% Approved · of votes cast

FOR 71%AGAINST
FOR: 28,069,401AGAINST: 11,693,213
Details: description as filed, official tally, votes by 92 asset managers

Description as filed by funds: To approve the amendment and restatement of our 2015 Equity Incentive Plan.

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan")”): 28,069,401 for, 11,693,213 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan");”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AMPHASTAR PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, 1,229,081 against).

The 92 asset managers below reported 11,189,376 for, 4,943,221 against, 6,769 abstained.

FORAGAINST
FOR: 11,189,376AGAINST: 4,943,221ABSTAIN: 6,769
Largest asset managers voting on “To approve the amendment and restatement of our 2015 Equity Incentive Plan.” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Neuberger Berman1,108,3100 00For
Dimensional0830,819 00Against
Fidelity727,61466,491 00Mixed
State Street4,017631,991 00Against
American Century0634,419 00Against
T. Rowe Price0439,674 00Against
OBERWEIS FUNDS0394,600 00Against
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC0283,135 00Against
Invesco0268,041 00Against
Victory Capital0190,615 00Against
TIAA187,1110 00For
Janus Detroit Street Trust0134,139 00Against
Brighthouse101,04814,440 00Mixed
Equitable57,90146,100 00Mixed
Columbia Threadneedle0101,339 00Against
MoA Funds Corp096,332 00Against
Jackson National094,238 00Against
World Funds Trust074,562 00Against
SEI74,3120 00For
BNY Mellon071,129 00Against
QUANTITATIVE MASTER SERIES LLC70,4020 00For

Showing the 25 largest of 92 asset managers. All 92 are in the interactive database (link above).

To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 37,859,745AGAINST: 1,833,819

Prior year: 96.7% for (June 5, 2023 meeting) ▼ 1.3 pts

Details: description as filed, official tally, votes by 299 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers; and

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and”): 37,859,745 for, 1,833,819 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 92 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers; and” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust1,200,1920 00For
Neuberger Berman1,108,3100 00For
Dimensional830,8190 00For
Fidelity794,1050 00For
State Street633,7292,279 00For
American Century0634,419 00Against
T. Rowe Price439,6740 00For
OBERWEIS FUNDS394,6000 00For
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC283,1350 00For
Invesco268,0410 00For
Victory Capital190,6150 00For
TIAA187,1110 00For
Janus Detroit Street Trust134,1390 00For
Brighthouse115,4880 00For
Equitable104,0010 00For
Columbia Threadneedle101,3390 00For
MoA Funds Corp96,3320 00For
Jackson National94,2380 00For
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon71,1290 00For

Fund voting reports, all 92 managers: 16,672,917 for, 691,050 against, 4,323 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 233 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers; and” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Federated Hermes2,046,3950 00For
Neuberger Berman1,658,0190 00For
State Street1,369,64914,630 00For
FULLER & THALER ASSET MANAGEMENT, INC.1,257,9390 00For
BlackRock1,117,18021,651 00For
GEODE CAPITAL MANAGEMENT, LLC757,6660 00For
American Century0638,974 00Against
BOONE CAPITAL MANAGEMENT LLC575,5470 00For
Epoch Investment Partners, Inc.573,2630 00For
T. Rowe Price523,0790 00For
Northern Trust453,3411,730 00For
OBERWEIS ASSET MANAGEMENT INC/398,3000 00For
Charles Schwab358,6380 00For
NORDEA INVESTMENT MANAGEMENT AB0333,014 00Against
Granite Investment Partners, LLC311,7080 00For
Invesco291,8380 00For
BESSEMER INVESTMENT MANAGEMENT LLC283,1350 00For
Point72270,2920 00For
PRINCIPAL GLOBAL INVESTORS218,6640 00For
Victory Capital205,2465,864 00For
MELLON INVESTMENTS Corp204,1980 00For
Nuveen188,6610 00For
Bessemer Trust CO of Delaware, N.A.178,0790 00For
Mesirow Institutional Investment Management, Inc.50,714126,223 00Mixed
BESSEMER TRUST Co NATIONAL ASSOCIATION163,7490 00For

Institutional-manager reports, all 233 managers: 16,711,383 for, 1,575,091 against, 671 abstained, 58 not voted. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 44,072,994AGAINST: 586,017

Prior year: 98.6% for (June 5, 2023 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024;

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024”): 44,072,994 for, 586,017 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 17,363,608 for, 516 against, 4,323 abstained.

FOR
FOR: 17,363,608AGAINST: 516ABSTAIN: 4,323
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,590,7220 00For
Vanguard2,618,0700 00For
Federated Hermes2,046,3940 00For
Capitol Series Trust1,200,1920 00For
Neuberger Berman1,108,3100 00For
Dimensional830,8190 00For
Fidelity794,1050 00For
State Street635,492516 00For
American Century634,4190 00For
T. Rowe Price439,6740 00For
OBERWEIS FUNDS394,6000 00For
Charles Schwab342,8040 00For
OLD WESTBURY FUNDS INC283,1350 00For
Invesco268,0410 00For
Victory Capital190,6150 00For
TIAA187,1110 00For
Janus Detroit Street Trust134,1390 00For
Brighthouse115,4880 00For
Equitable104,0010 00For
Columbia Threadneedle101,3390 00For
MoA Funds Corp96,3320 00For
Jackson National94,2380 00For
World Funds Trust74,5620 00For
SEI74,3120 00For
BNY Mellon71,1290 00For

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Largest AMPHASTAR PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 48,841,343 shares outstanding at the time of that meeting.

Fund voting reports: top AMPHASTAR PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1BlackRock 7.35%
2Vanguard 5.36%
3Federated Hermes 4.19%
4Capitol Series Trust 2.46%
5Neuberger Berman 2.27%
6Dimensional 1.70%
7Fidelity 1.63%
8State Street 1.30%
9American Century 1.30%
10T. Rowe Price 0.90%
Institutional-manager reports: top AMPHASTAR PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Federated Hermes 4.19%
2Neuberger Berman 3.39%
3State Street 2.83%
4FULLER & THALER ASSET MANAGEMENT, INC. 2.58%
5BlackRock 2.33%
6GEODE CAPITAL MANAGEMENT, LLC 1.55%
7American Century 1.31%
8BOONE CAPITAL MANAGEMENT LLC 1.18%
9Epoch Investment Partners, Inc. 1.17%
10T. Rowe Price 1.07%

Reported AMPHASTAR PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

AMPHASTAR PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Jack Yongfeng Zhang13,435,210 —Schedule 13G, filed February 9, 2024
Jack Y. Zhang12,774,153 —Proxy statement (DEF 14A), proxy filed April 12, 2024
Mary Z. Luo12,774,153 —Proxy statement (DEF 14A), proxy filed April 12, 2024
Applied Physics & Chemistry Laboratories, Inc.6,827,679 —Proxy statement (DEF 14A), proxy filed April 12, 2024
BlackRock5,485,057 —Form 13F, quarter ended March 31, 2024
Vanguard Group2,631,040 —Form 13F, quarter ended March 31, 2024
State Street1,514,249 —Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors1,183,830 —Form 13F, quarter ended March 31, 2024
Geode Capital866,032 —Form 13F, quarter ended March 31, 2024
Renaissance Technologies599,100 —Form 13F, quarter ended March 31, 2024

Percentages above are of 48,841,343 shares outstanding, as reported by AMPHASTAR PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At AMPHASTAR PHARMACEUTICALS INC.'s shareholder meeting held June 3, 2024, in the 2023-2024 proxy season, 299 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 2,413 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — AMPHASTAR PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AMPHASTAR PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMPHASTAR PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

AMPHASTAR PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “AMPHASTAR PHARMACEUTICALS (AMPH) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amphastar-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.